Vertex Pharmaceuticals Incorporated
VRTX Healthcare Biotechnology
Vertex Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.0 billion, up 8.90% from fiscal 2024. In the quarter to June 2026, revenue grew 12.5%, EPS grew 7.96% and free cash flow grew 9.25%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years.
Follow VRTX
Vertex Pharmaceuticals Incorporated (VRTX) Shares outstanding
Vertex Pharmaceuticals Incorporated's shares outstanding at the end of fiscal 2025 was $258.0M, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $255.2M. Over the past ten years it has ranged from $241.3M (fiscal 2015) to $263.4M (fiscal 2020); the current reading is higher than 45% of that period. Vertex Pharmaceuticals Incorporated ranks 29th of 602 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $258.0M | 0.04% |
| FY2024 | $257.9M | (1.00%) |
| FY2023 | $260.5M | 0.54% |
| FY2022 | $259.1M | (0.31%) |
| FY2021 | $259.9M | (1.33%) |
| FY2020 | $263.4M | 1.04% |
| FY2019 | $260.7M | 0.58% |
| FY2018 | $259.2M | 2.35% |
| FY2017 | $253.2M | 3.49% |
| FY2016 | $244.7M | 1.40% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $255.2M | (0.43%) |
| Mar 2026 | $256.3M | (0.66%) |
| Dec 2025 | $258.0M | 0.16% |
| Sep 2025 | $257.6M | (0.50%) |
| 42 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| ROIV Roivant Sciences Ltd. compare | $720.8M |
| RPRX Royalty Pharma PLC compare | $556.9M |
| MRNA Moderna, Inc. compare | $398.0M |
| VRTX Vertex Pharmaceuticals Incorporated | $255.2M |
| RVMD Revolution Medicines, Inc. compare | $210.9M |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $138.3M |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $115.8M |
| REGN Regeneron Pharmaceuticals, Inc. compare | $106.0M |
| ARGX argenex SE compare | $64.5M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on VRTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement